CDC Unveils Meticulous Process for Pandemic-Ready Flu Vaccines

Researchers detail the CDC's comprehensive approach to developing influenza candidate vaccine viruses for rapid pandemic response.

Apr. 11, 2026 at 7:21am

Got story updates? Submit your updates here. ›

An extreme close-up X-ray photograph revealing the internal structures of a glass vial containing influenza vaccine viruses as glowing, ghostly lines against a dark background, conceptually illustrating the CDC's work in preparing for the next pandemic.The CDC's meticulous process for developing pandemic-ready influenza vaccines involves creating optimized candidate viruses that can be rapidly mass-produced when needed.Cleveland Today

The U.S. Centers for Disease Control and Prevention (CDC) has revealed the intricate process behind developing influenza candidate vaccine viruses (CVVs) that are ready for pandemic deployment. Researchers describe the CDC's meticulous protocols, from maintaining a sterile workspace to leveraging global surveillance data, to ensure these critical vaccine seeds can be mass-produced efficiently when needed to combat the next global health crisis.

Why it matters

Influenza remains a major global threat, causing up to 650,000 deaths annually. The CDC's CVV development process is crucial for rapidly producing pandemic influenza vaccines and bolstering worldwide preparedness, especially in light of the devastating impact of the recent COVID-19 pandemic.

The details

The CDC, in collaboration with partners like the National Institutes of Health and World Health Organization, develops and maintains these CVVs, which are specifically designed for efficient growth in chicken eggs to serve as primary vaccine seeds. The production process adheres to stringent quality control measures, including decontaminated workspaces, global virus surveillance, plasmid cloning, virus production, HA assays, and comprehensive quality control testing.

  • The CDC's CVV production process has supported the development of over 100 CVVs to date.
  • 36 of these CVVs have been distributed to vaccine manufacturers, academic researchers, and other stakeholders.

The players

U.S. Centers for Disease Control and Prevention (CDC)

The leading national public health institute in the United States, responsible for protecting public health and safety through the control and prevention of disease, injury, and disability.

U.S. National Institutes of Health (NIH)

The primary agency of the United States government responsible for biomedical and public health research.

World Health Organization (WHO)

The specialized agency of the United Nations responsible for international public health.

Biomedical Advanced Research and Development Authority (BARDA)

A division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, supporting the development and procurement of medical countermeasures.

Quality Assurance Unit (QAU)

The team within the CDC Influenza Division responsible for meticulously inspecting all raw materials and reagents before any experiments begin.

Got photos? Submit your photos here. ›

What’s next

The CDC and its partners continue to refine and improve the CVV production process, exploring advancements in recombinant protein- and nucleic acid-based vaccine platforms to enable rapid antigen redesign for improved pandemic responsiveness.

The takeaway

The CDC's transparent approach to CVV development highlights the critical importance of global health preparedness and the ongoing efforts to build a robust defense against potential pandemics. By understanding these complex processes, the public can appreciate the diligence and innovation required to safeguard public health.